DOCSLIB.ORG

Y-Carboxyglutamic Acids 36 and 40 Do Not Contribute to Human Factor IX Function

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Y-Carboxyglutamic Acids 36 and 40 Do Not Contribute to Human Factor IX Function Protein Science (1997), 6185-196. Cambridge University Press. Printed in the USA. Copyright 0 1997 The Protein Society y-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function SHMUEL GILLIS,' BARBARA C. FURIE,' BRUCE FURIE,' HIMAKSHI PATEL: MICHAEL C. HUBERTY: MARY SWITZER: W. BARRY FOSTER: HUBERT A. SCOBLE: AND MICHAEL D. BOND* 'The Center for Hemostasis and Thrombosis Research, Division of Hematology-Oncology, New England Medical Center, Department of Medicine and Department of Biochemistry, Tufts University School of Medicine, Boston, Massachusetts 'Genetics Institute Inc., Andover, Massachusetts (RECEIVED September 9, 1996 ACCEP~EDOctober 16, 1996) Abstract The y-carboxyglutamic acid (Gla) domains of the vitamin K-dependent blood coagulation proteins contain 10 highly conserved Gla residues within the first 33 residues, but factor IX is unique in possessing 2 additional Gla residues at positions 36 and 40. To determine their importance, factor IX species lacking these Gla residues were isolated from heterologously expressed human factor IX. Using ion-exchange chromatography, peptide mapping, mass spectrometry, and N-terminal sequencing, we have purified and identified two partially carboxylated recombinant factor IX species; factor IXIy40E is uncarboxylated at residue 40 and factor IX/y36,40E is uncarboxylated at both residues 36 and 40. These species were compared with the fully y-carboxylated recombinant factor IX, unfractionated recombinant fac- tor IX, and plasma-derived factor IX. As monitored by anti-factor IX:Ca(II)-specific antibodies and by the quenching of intrinsic fluorescence, all these factor IX speciesunderwent the Ca(I1)-induced conformational transition required for phospholipid membrane binding and bound equivalently to phospholipid vesicles composed of phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. Endothelial cell binding was also similar in all species, with half-maximal inhibition of the binding of 1251-labeledplasma-derived factor IX at concentrations of 2-6 nM. Func- tionally, factor IX/y36,40E and factor IXIy40E were similar to fully y-carboxylated recombinant factor IX and plasma-derived factor IX in their coagulant activity and in their ability to participate in the activation of factor X in the tenase complex both with synthetic phospholipid vesicles and activated platelets. However, Gla 36 and Gla 40 represent part of the epitope targeted by anti-factor IX:Mg(II)-specific antibodies because these antibodies bound factor IX preferentially to factor IXly36,40E and factor IXIy40E. These results demonstrate that the y-carboxylation of glutamic acid residues 36 and 40 in human factor IX is not required for any function of factor IX examined. Keywords: calcium-binding protein; Gla; hemophilia B; vitamin K Factor IX is a vitamin K-dependent plasma zymogen that plays a function requires the presence of Gla residues that participate di- central role in blood coagulation. Patients deficient in factor IX rectly in Ca(I1) binding via their malonate side chains (Furie & activity have the bleeding disorder hemophilia B. In common with Furie, 1988; Freedman et al., 1995a). Gla is formed by a post- the other vitamin-K dependent blood coagulation proteins, fac- translational modification in which glutamic acid residues undergo tor IX contains an amino-terminal Gla domain that is responsible y-carboxylation mediated by the enzyme y-glutamyl carboxylase for its phospholipid binding properties (Furie & Furie, 1988). This (Furie & Furie, 1988). The Gla domains in the vitamin-K depen- dent proteins contain 9-12 Gla residues; of these, the N-terminal nine Gla residues are fully conserved and the tenth is highly con- Reprint requests to: BNce Furie* Division Of Hematology-oncology, served, Factor IX is unique in possessing two additional distal GIa New England Medical Center, 750 Washington St., Boston, Massachusetts 02111_-.._. residues at positions40 36 and (Vermeer, 1990). Abbreviurions: AAAS, aromaticamino acid stack; Achro-K, Achromo- The rnetal-free and calcium ion-bound structures of the fac- bacter Protease I; DHB, 2,5-dihy&oxybenzoic acid; dPE, dansyl-phospha- tor IX Gla and AAAS domains have been determined recently by tidylethanolamine; EGE epidermal growth factor; Gla, y-cahwglutamic NMR spectroscopy (Freedman et al., 1995a, 1995b). nemetal-free acid; HMB, 2-hydroxy-5-methoxybenzoicacid; MALDI-TOF MS, matrix assisted laser desorption ionization time-of-flight maSSspectromeny; PACE, structure is relatively disordered, whereas the calcium ion-bound paired basic amino acid cleaving enzyme; PC, phosphatidylcholine; PITC, form is substantially ordered, consisting of a large amino-terminal phenylisothiocyanate; PS, phosphatidylserine. loop (residues 1-12), three helical segments (residues 14-17,25-32, 185 S. Gillis et al. and 35-46), and a disulfide loop (residues 18-23). The three- dimensional structure of the polypeptide backbone of the calcium- bound form is very similar to that of prothrombin fragment 1 (Soriano-Garcia et al., 1992), but small differences in the N-terminal loop may befunctionally important. In the calcium ion-bound form, the amino-terminal nine Gla residues are oriented to the interior of the protein, consistent with an internal Ca(I1) binding pocket. Gla residues 33, 36, and 40 are on the solvent-exposed surface of the calcium ion-bound structure. Their role has not been defined. Gla 40 has been postulated to be required for the stabilization of the Gla domain carboxyl-terminal a-helix through ionic interactions (Freed- man et al., 1995a). Others have suggested, based on the X-ray struc- ture of the factor IX EGF-like domain, that Gla 40 may be a Ca(I1) binding site required for the correct folding of the EGF domain over the adjacent Gla domain (Rao et al., 1995). MINUTES Gla at residue 33 may be important for factor IX activity be- cause a mutation of the equivalent residue in prothrombin to as- Rec. Factor IX partic acid yielded aprotein with reduced coagulantactivity (Ratcliffe et al., 1993). A Gla to Asp mutation at residue 33 causes a severe deficiency in factor IX in a patient with hemophilia B; E however, the specific activity of this mutant is not known (Koeberl et al., 1989). The importance of Gla 36 and Gla 40 in factor IX N function remains unknown. Recombinant factor IX, in contrast to recombinant prothrombin (Jorgensen et al., 1987; Ratcliffe et al., 1993), has been found to be under-y-carboxylated, especially when expressed at high levels (Kaufman et al., 1986; Derian et al., 1989). In this report, we describe the isolation and purification of two partially y-carboxylated species of recombinant factor IX and demonstrate that they are 0 20 40 lacking y-carboxylation either at residue 40 or at both residues 36 MINUTES and 40. We have characterized these species functionally and com- pared them with plasma-derived human factor IX. We show that Gla 36 and Gla 40 are not required for any function of human 01 factor IX that was examined. Results Factor IX undergoes numerous posttranslational modifications, in- cluding the y-carboxylation of 12 glutamic acid residues in the Gla and AAAS domains (Furie & Furie, 1988; Vermeer, 1990), P-hydroxylation of Asp 64 (Femlund & Stenflo, 1983; Furie & Furie, 1988), and 0-glycosylation of two sites in the first EGF domain, at Ser 53 and Ser 61, the latter of which contains sialic 0 I acid (Bharadwaj et al., 1995). The activation peptide contains sev- 0 20 40 eral glycosylation, sulfation, and phosphorylation sites (Agarwala MINUTES et al., 1994; Bond et al., 1994a). In order to obtain species of Fig. 1. Mono Q HPLC separation of recombinant factor IX species. A: factor IX that lack Gla at specific residues, we fractionated recom- Recombinant factor IX samples were prepared in 20 mM Tris, pH 9.0, and binant factor IX expressed in Chinese hamster ovary cells. This injected in volumes of 0.1-2.0 mL. Elution employed a 0.3-0.4 M NaCl expression system yields nearly completely processed factor IX, gradient. Sample A represents results for a typical sample of recombinant factor IX. Sample B represents a sample with unusually high levels of but a component of recombinant factor IX is undercarboxylated peak 1. B: factor IX was analyzed by Mono Q chromatography as above, and thus served as a sourceof homogeneous partially carboxylated before and after removal of sialic acids with neuraminidase. C: Mono Q factor IX. chromatography before and after activation of recombinant factor IX with Application of unfractionated recombinant factor IX to a Mono Q factor XIa (1 :200, w/w) in 50 mM Tris, 0.15 M NaCI, 5 mM CaCI2, pH 7.5, ion exchange chromatography column yielded three major frac- for 1 h at 37°C. tions observed as peaks 1, 2, and 3. Peak 3 included a small shoul- der (Fig. 1A). To determine which modifications were responsible for the multiple species observed by ion exchange chromatography, tion differences. A sample of recombinant factor IX was also stud- a sample of recombinant factor IX was analyzed before and after ied before and after activation with factor XIa, a process that removes enzymatic desialylation. Desialylation induced a shift in retention the activation peptide (and any modifications therein). The chro- times, but did not change the chromatographic profile (Fig. 1B). matogram again demonstrated the same three major peaks, and there Therefore, the observed fractionation does not result from sialyla- was no shift in the retention times (Fig. IC). The results show that Gla 36 and Gla 40 of human factor TX 187 Table 1. Gla content of Mono Q purified recombinant factor IX speciesa 0.2 Species mol Gldmol protein Peak 1 10.3 -C 0.3 Peak 2 11.2 * 0.2 0 Peak 3 12.1 * 0.2 12-Gla Species Unfractionatedrecombinant factor IX 11.5 f 0.2 K3[6-Gla] Plasma-derived factor IX 12.0 * 0.3 Factor X 10.6 f 0.3 : 0.1 "Gla content was determined by amino acid analysis following alkaline v -0 hydrolysis as described in Materials and methods.The raw values of mol Glal N mol protein for each sample was normalized to yield mol Glahol ui 11-Gla Species 12.0 P protein for the plasma-derived factor included in each set of assays.
Load more

Recommended publications
  • The Role of High Density Lipoprotein Compositional and Functional Heterogeneity in Metabolic Disease
    The role of high density lipoprotein compositional and functional heterogeneity in metabolic disease By Scott M. Gordon B.S. State University of New York College at Brockport October, 2012 A Dissertation Presented to the Faculty of The University of Cincinnati College of Medicine in partial fulfillment of the requirements for the Degree of Doctor of Philosophy from the Pathobiology and Molecular Medicine graduate program W. Sean Davidson Ph.D. (Chair) David Askew Ph.D. Professor and Thesis Chair Professor Department of Pathology Department of Pathology University of Cincinnati University of Cincinnati Francis McCormack M.D. Gangani Silva Ph.D. Professor Assistant Professor Department of Pathology Department of Pathology University of Cincinnati University of Cincinnati Jason Lu Ph.D. Assistant Professor Division of Bioinformatics Cincinnati Children’s Hospital i Abstract High density lipoproteins (HDL) are complexes of phospholipid, cholesterol and protein that circulate in the blood. Epidemiological studies have demonstrated a strong inverse correlation between plasma levels of HDL associated cholesterol (HDL-C) and the incidence of cardiovascular disease (CVD). Clinically, HDL-C is often measured and used in combination with low density lipoprotein cholesterol (LDL-C) to assess overall cardiovascular health. HDL have been shown to possess a wide variety of functional attributes which likely contribute to this protection including anti-inflammatory and anti- oxidative properties and the ability to remove excess cholesterol from peripheral tissues and deliver it to the liver for excretion, a process known as reverse cholesterol transport. This functional diversity might be explained by the complexity of HDL composition. Recent studies have taken advantage of advances in mass spectrometry technologies to characterize the proteome of total HDL finding that over 50 different proteins can associate with these particles.
    [Show full text]
  • Platelet Function Disorders
    TREATMENT OF HEMOPHILIA APRIL 2008 • NO 19 PLATELET FUNCTION DISORDERS Second Edition Anjali A. Sharathkumar Amy Shapiro Indiana Hemophilia and Thrombosis Center Indianapolis, U.S.A. Published by the World Federation of Hemophilia (WFH), 1999; revised 2008. © World Federation of Hemophilia, 2008 The WFH encourages redistribution of its publications for educational purposes by not-for-profit hemophilia organizations. In order to obtain permission to reprint, redistribute, or translate this publication, please contact the Communications Department at the address below. This publication is accessible from the World Federation of Hemophilia’s website at www.wfh.org. Additional copies are also available from the WFH at: World Federation of Hemophilia 1425 René Lévesque Boulevard West, Suite 1010 Montréal, Québec H3G 1T7 CANADA Tel. : (514) 875-7944 Fax : (514) 875-8916 E-mail: [email protected] Internet: www.wfh.org The Treatment of Hemophilia series is intended to provide general information on the treatment and management of hemophilia. The World Federation of Hemophilia does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. Dose schedules and other treatment regimes are continually revised and new side effects recognized. WFH makes no representation, express or implied, that drug doses or other treatment recommendations in this publication are correct. For these reasons it is strongly recommended that individuals seek the advice of a medical adviser and/or consult printed instructions provided by the pharmaceutical company before administering any of the drugs referred to in this monograph. Statements and opinions expressed here do not necessarily represent the opinions, policies, or recommendations of the World Federation of Hemophilia, its Executive Committee, or its staff.
    [Show full text]
  • Download, Or Email Articles for Individual Use
    Florida State University Libraries Faculty Publications The Department of Biomedical Sciences 2010 Functional Intersection of the Kallikrein- Related Peptidases (KLKs) and Thrombostasis Axis Michael Blaber, Hyesook Yoon, Maria Juliano, Isobel Scarisbrick, and Sachiko Blaber Follow this and additional works at the FSU Digital Library. For more information, please contact [email protected] Article in press - uncorrected proof Biol. Chem., Vol. 391, pp. 311–320, April 2010 • Copyright ᮊ by Walter de Gruyter • Berlin • New York. DOI 10.1515/BC.2010.024 Review Functional intersection of the kallikrein-related peptidases (KLKs) and thrombostasis axis Michael Blaber1,*, Hyesook Yoon1, Maria A. locus (Gan et al., 2000; Harvey et al., 2000; Yousef et al., Juliano2, Isobel A. Scarisbrick3 and Sachiko I. 2000), as well as the adoption of a commonly accepted Blaber1 nomenclature (Lundwall et al., 2006), resolved these two fundamental issues. The vast body of work has associated 1 Department of Biomedical Sciences, Florida State several cancer pathologies with differential regulation or University, Tallahassee, FL 32306-4300, USA expression of individual members of the KLK family, and 2 Department of Biophysics, Escola Paulista de Medicina, has served to elevate the importance of the KLKs in serious Universidade Federal de Sao Paulo, Rua Tres de Maio 100, human disease and their diagnosis (Diamandis et al., 2000; 04044-20 Sao Paulo, Brazil Diamandis and Yousef, 2001; Yousef and Diamandis, 2001, 3 Program for Molecular Neuroscience and Departments of 2003;
    [Show full text]
  • Replacing the First Epidermal Growth Factor-Like Domain of Factor IX with That of Factor VII Enhances Activity in Vitro and in Canine Hemophilia B
    Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. J Y Chang, … , K M Brinkhous, H R Roberts J Clin Invest. 1997;100(4):886-892. https://doi.org/10.1172/JCI119604. Research Article Using the techniques of molecular biology, we made a chimeric Factor IX by replacing the first epidermal growth factor- like domain with that of Factor VII. The resulting recombinant chimeric molecule, Factor IXVIIEGF1, had at least a twofold increase in functional activity in the one-stage clotting assay when compared to recombinant wild-type Factor IX. The increased activity was not due to contamination with activated Factor IX, nor was it due to an increased rate of activation by Factor VIIa-tissue factor or by Factor XIa. Rather, the increased activity was due to a higher affinity of Factor IXVIIEGF1 for Factor VIIIa with a Kd for Factor VIIIa about one order of magnitude lower than that of recombinant wild- type Factor IXa. In addition, results from animal studies show that this chimeric Factor IX, when infused into a dog with hemophilia B, exhibits a greater than threefold increase in clotting activity, and has a biological half-life equivalent to recombinant wild-type Factor IX. Find the latest version: https://jci.me/119604/pdf Replacing the First Epidermal Growth Factor-like Domain of Factor IX with That of Factor VII Enhances Activity In Vitro and in Canine Hemophilia B Jen-Yea Chang,* Dougald M. Monroe,* Darrel W. Stafford,*‡ Kenneth M.
    [Show full text]
  • Activation Profiles and Regulatory Cascades of the Human Kallikrein-Related Peptidases Hyesook Yoon
    Florida State University Libraries Electronic Theses, Treatises and Dissertations The Graduate School 2008 Activation Profiles and Regulatory Cascades of the Human Kallikrein-Related Peptidases Hyesook Yoon Follow this and additional works at the FSU Digital Library. For more information, please contact [email protected] FLORIDA STATE UNIVERSITY COLLEGE OF ARTS AND SCIENCES ACTIVATION PROFILES AND REGULATORY CASCADES OF THE HUMAN KALLIKREIN-RELATED PEPTIDASES By HYESOOK YOON A Dissertation submitted to the Department of Chemistry and Biochemistry in partial fulfillment of the requirements for the degree of Doctor of Philosophy Degree Awarded: Fall Semester, 2008 The members of the Committee approve the dissertation of Hyesook Yoon defended on July 10th, 2008. ________________________ Michael Blaber Professor Directing Dissertation ________________________ Hengli Tang Outside Committee Member ________________________ Brian Miller Committee Member ________________________ Oliver Steinbock Committee Member Approved: ____________________________________________________________ Joseph B. Schlenoff, Chair, Department of Chemistry and Biochemistry The Office of Graduate Studies has verified and approved the above named committee members. ii ACKNOWLEDGMENTS I would like to dedicate this dissertation to my parents for all your support, and my sister and brother. I would also like to give great thank my advisor, Dr. Blaber for his patience, guidance. Without him, I could never make this achievement. I would like to thank to all the members in Blaber lab. They are just like family to me and I deeply appreciate their kindness, consideration and supports. I specially like to thank to Mrs. Sachiko Blaber for her endless guidance and encouragement. I would like to thank Dr Jihun Lee, Margaret Seavy, Rani and Doris Terry for helpful discussions and supports.
    [Show full text]
  • A Genomic Analysis of Rat Proteases and Protease Inhibitors
    A genomic analysis of rat proteases and protease inhibitors Xose S. Puente and Carlos López-Otín Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología, Universidad de Oviedo, 33006-Oviedo, Spain Send correspondence to: Carlos López-Otín Departamento de Bioquímica y Biología Molecular Facultad de Medicina, Universidad de Oviedo 33006 Oviedo-SPAIN Tel. 34-985-104201; Fax: 34-985-103564 E-mail: [email protected] Proteases perform fundamental roles in multiple biological processes and are associated with a growing number of pathological conditions that involve abnormal or deficient functions of these enzymes. The availability of the rat genome sequence has opened the possibility to perform a global analysis of the complete protease repertoire or degradome of this model organism. The rat degradome consists of at least 626 proteases and homologs, which are distributed into five catalytic classes: 24 aspartic, 160 cysteine, 192 metallo, 221 serine, and 29 threonine proteases. Overall, this distribution is similar to that of the mouse degradome, but significatively more complex than that corresponding to the human degradome composed of 561 proteases and homologs. This increased complexity of the rat protease complement mainly derives from the expansion of several gene families including placental cathepsins, testases, kallikreins and hematopoietic serine proteases, involved in reproductive or immunological functions. These protease families have also evolved differently in the rat and mouse genomes and may contribute to explain some functional differences between these two closely related species. Likewise, genomic analysis of rat protease inhibitors has shown some differences with the mouse protease inhibitor complement and the marked expansion of families of cysteine and serine protease inhibitors in rat and mouse with respect to human.
    [Show full text]
  • Coagulation Simplified…
    Coagulation Simplified… Published by ACKNOWLEDGEMENTS CONTENTS We gratefully acknowledge the support and funding provided by the Ontario Ministry of Health 1. The Basics of Coagulation and Clot Breakdown . 4–7 and Long-Term Care. 2. Routine Coagulation Tests . 8–17 Special thanks to the following people and organizations who provided their expertise in Evaluating coagulation in the laboratory . 8 reviewing the content of this handbook: Sample collection for coagulation testing . 9 Prothrombin Time (PT) . 10 L Gini Bourner (QMP-LS Hematology Committee) International Normalized Ratio (INR) . 11 L Dr. Jeannie Callum Activated Partial Thromboplastin Time (APTT) . 12 L Dr. Allison Collins Thrombin Time (TT) . 13 Fibrinogen . 14 L Dr. William Geerts D-dimer . 15 L Dr. Alejandro Lazo-Langner Anti-Xa assay . 16 L Dr. Ruth Padmore (QMP-LS Hematology Committee) Summary . 17 L Anne Raby (QMP-LS Hematology Committee) 3. Anticoagulant Drugs . 18–25 L Dr. Margaret Rand Unfractionated Hepari n (UFH) . 18 L Dr. Alan Tinmouth Low Molecular Weight Heparins (LMWHs) . 19 Fondaparinux . 20 Warfarin . 21 Thanks also to: Direct Thrombin Inhibitors (DTI) . 23 L Dale Roddick, photographer, Sunnybrook Health Sciences Centre Direct Xa Inhibitors . 25 L Reena Manohar, graphic artist, Sunnybrook Health Sciences Centre 4. Evaluating Abnormal Coagulation Tests . 26–29 L The ECAT Foundation Prolonged PT / INR with normal APTT . 26 CLOT-ED Images used or modified with permission from Prolonged APTT with normal PT / INR . 27 the ECAT Foundation, The Netherlands. Prolonged APTT and PT / INR . 28 Prolonged Thrombin Time (TT) with normal or prolonged APTT and PT / INR . 29 March 2013 5. Approach to the Evaluation of the Bleeding Patient .
    [Show full text]
  • Natural and Engineered Kallikrein Inhibitors: an Emerging Pharmacopoeia
    Article in press - uncorrected proof Biol. Chem., Vol. 391, pp. 357–374, April 2010 • Copyright ᮊ by Walter de Gruyter • Berlin • New York. DOI 10.1515/BC.2010.037 Review Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia Joakim E. Swedberg, Simon J. de Veer and ulated activation cascades, suggesting an involvement in a Jonathan M. Harris* diverse range of physiological processes (Pampalakis and Sotiropoulou, 2007). Both liver-derived KLKB1 and tissue- Institute of Health and Biomedical Innovation, Queensland derived KLK1, as well as KLK2 and KLK12 in vitro (Giusti University of Technology, Brisbane, Queensland 4059, et al., 2005), participate in the progressive activation of Australia bradykinin, a bioactive peptide involved in blood pressure * Corresponding author homeostasis and inflammation initiation (Bhoola et al., e-mail: [email protected] 1992). Although this is the only demonstration of classical kininogenic activity that was the original hallmark of kallik- Abstract rein proteases, the contribution of subsets of KLKs to vital physiological processes is well appreciated. Prostate- The kallikreins and kallikrein-related peptidases are serine expressed KLK2, 3, 4, 5 and 14 are involved in seminogelin proteases that control a plethora of developmental and home- hydrolysis (Lilja, 1985; Deperthes et al., 1996; Takayama et ostatic phenomena, ranging from semen liquefaction to skin al., 2001b; Michael et al., 2006; Emami and Diamandis, desquamation and blood pressure. The diversity of roles 2008), KLK6 and 8 have reported functions in defining neu- played by kallikreins has stimulated considerable interest in ral plasticity (Shimizu et al., 1998; Scarisbrick et al., 2002; these enzymes from the perspective of diagnostics and drug Tamura et al., 2006; Ishikawa et al., 2008) and KLK5, 7, 8 design.
    [Show full text]
  • TMEM16F Is Required for Phosphatidylserine Exposure and Microparticle Release in Activated Mouse Platelets
    TMEM16F is required for phosphatidylserine exposure and microparticle release in activated mouse platelets Toshihiro Fujiia,b, Asuka Sakatac, Satoshi Nishimurac,d, Koji Etoe, and Shigekazu Nagataa,b,1 aLaboratory of Biochemistry & Immunology, Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan; bCore Research for Evolutional Science and Technology, Japan Science and Technology Agency, Saitama 332-0012, Japan; cCenter for Molecular Medicine, Jichi Medical University, Tochigi 329-0498, Japan; dDepartment of Cardiovascular Medicine, The University of Tokyo, Tokyo 113-0033, Japan; and eDepartment of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan Contributed by Shigekazu Nagata, August 20, 2015 (sent for review July 13, 2015; reviewed by Yuzuru Kanakura, Tatsutoshi Nakahata, and Kiyoshi Takatsu) + Phosphatidylserine (PtdSer) exposure on the surface of activated only a mild defect in Ca2 ionophore–induced PtdSer exposure and platelets requires the action of a phospholipid scramblase(s), and tissue factor-induced thrombin generation. Furthermore, in contrast serves as a scaffold for the assembly of the tenase and prothrombi- to a human patient with Scott syndrome (14) and dogs with a similar nase complexes involved in blood coagulation. Here, we found that hereditary syndrome (15), neither of which exhibits apparent + − − the activation of mouse platelets with thrombin/collagen or Ca2 bleeding-time defects, TMEM16F / mice exhibit a prolonged ionophore at 20 °C induces PtdSer exposure without compromising bleeding time—twice that of WT mice (13). − − plasma membrane integrity. Among five transmembrane protein 16 To address the apparent discrepancies between TMEM16F / + (TMEM16) members that support Ca2 -dependent phospholipid mouse phenotypes and the clinical presentation of patients with scrambling, TMEM16F was the only one that showed high expres- Scott syndrome, and to examine the role of platelet-expressed sion in mouse platelets.
    [Show full text]
  • Combinatorial Targeting of the Androgen Receptor for Prostate
    Combinatorial Targeting of the Androgen Receptor for Prostate Cancer Therapy A thesis submitted to the University of Adelaide in the fulfilment of the requirements for the degree of Doctor of Philosophy By Sarah Louise Carter B.BiomolChem.(Hons) Dame Roma Mitchell Cancer Research Laboratories School of Medicine The University of Adelaide and The Hanson Institute March 2015 Contents Chapter 1: General Introduction ........................................................................................1 1.1 Background ..................................................................................................................2 1.2 Androgens and the Prostate ..........................................................................................3 1.3 Androgen Signalling through the Androgen Receptor .................................................4 1.3.1 The androgen receptor (AR) ..................................................................................4 1.3.2 Androgen signalling in the prostate .......................................................................6 1.4 Current Treatment Strategies for Prostate Cancer ........................................................8 1.4.1 Diagnosis ...............................................................................................................8 1.4.2 Localised disease .................................................................................................10 1.4.3 Relapse and metastatic disease ............................................................................13
    [Show full text]
  • The Human KLK8 (Neuropsin/Ovasin) Gene: Identification of Two Novel Splice Variants and Its Prognostic Value in Ovarian Cancer
    806 Vol. 7, 806–811, April 2001 Clinical Cancer Research The Human KLK8 (Neuropsin/Ovasin) Gene: Identification of Two Novel Splice Variants and Its Prognostic Value in Ovarian Cancer Angeliki Magklara, Andreas Scorilas, KLK8 encodes for a predicted secreted protein, its detection Dionyssios Katsaros, Marco Massobrio, in serum may aid in ovarian cancer diagnosis. George M. Yousef, Stefano Fracchioli, 1 Saverio Danese, and Eleftherios P. Diamandis INTRODUCTION Department of Pathology and Laboratory Medicine, Mount Sinai The human kallikrein gene family is a subfamily of serine Hospital and Department of Laboratory Medicine and Pathobiology, proteases, located at the chromosomal locus 19q13.3–q13.4. University of Toronto, Toronto, Ontario, M5G 1X5 Canada [A. M., A. S., G. M. Y., E. P. D.], and Departments of Obstetrics and Until recently, this family was known to include only three Gynecology, Gynecologic Oncology Unit [D. K., M. M., S. F.] and members: the pancreatic/renal kallikrein gene (KLK1), the hu- Gynecology, S. Anna Hospital [S. D.], University of Turin, Turin man glandular kallikrein 2 gene (KLK2), and prostate-specific 10126, Italy antigen (KLK3). In the past few years, another 11 kallikrein-like genes were discovered (reviewed in Ref. 1). Neuropsin is one of ABSTRACT these genes that maps to this locus (1, 2). According to the KLK8 (neuropsin/ovasin) is a new member of the human approved human kallikrein gene nomenclature, neuropsin is also kallikrein gene family, which consists of enzymes with serine known as KLK8 (3). protease enzymatic activity. Recent reports have implicated Neuropsin is a well-characterized, brain-related serine KLK8 in ovarian cancer.
    [Show full text]
  • Blood Flow Controls Coagulation Onset Via the Positive Feedback of Factor
    Shibeko et al. BMC Systems Biology 2010, 4:5 http://www.biomedcentral.com/1752-0509/4/5 RESEARCH ARTICLE Open Access Blood flow controls coagulation onset via the positive feedback of factor VII activation by factor Xa Alexey M Shibeko1, Ekaterina S Lobanova1,2, Mikhail A Panteleev1,3, Fazoil I Ataullakhanov1,3,4* Abstract Background: Blood coagulation is a complex network of biochemical reactions, which is peculiar in that it is time- and space-dependent, and has to function in the presence of rapid flow. Recent experimental reports suggest that flow plays a significant role in its regulation. The objective of this study was to use systems biology techniques to investigate this regulation and to identify mechanisms creating a flow-dependent switch in the coagulation onset. Results: Using a detailed mechanism-driven model of tissue factor (TF)-initiated thrombus formation in a two- dimensional channel we demonstrate that blood flow can regulate clotting onset in the model in a threshold-like manner, in agreement with existing experimental evidence. Sensitivity analysis reveals that this is achieved due to a combination of the positive feedback of TF-bound factor VII activation by activated factor X (Xa) and effective removal of factor Xa by flow from the activating patch depriving the feedback of “ignition”. The level of this trigger (i.e. coagulation sensitivity to flow) is controlled by the activity of tissue factor pathway inhibitor. Conclusions: This mechanism explains the difference between red and white thrombi observed in vivo at different shear rates. It can be speculated that this is a special switch protecting vascular system from uncontrolled formation and spreading of active coagulation factors in vessels with rapidly flowing blood.
    [Show full text]